prednisolone + vancomycin

This is a combination therapy consisting of prednisolone, a synthetic glucocorticoid corticosteroid, and vancomycin, a glycopeptide antibiotic. Prednisolone acts as an agonist at the glucocorticoid receptor to suppress inflammation and immune responses by altering gene expression and reducing leukocyte migration. Vancomycin inhibits bacterial cell wall synthesis by binding to D-alanyl-D-alanine termini of peptidoglycan precursors, leading to bactericidal activity against Gram-positive bacteria. This combination has been used in clinical settings for severe infections or inflammatory conditions where both immunosuppression (to control autoimmune or inflammatory processes) and potent antibacterial action (especially against resistant Gram-positive organisms) are required. Clinical reports describe its use in steroid-refractory ulcerative colitis with suspected infectious triggers[2], as well as adjunctive therapy in severe bacterial meningitis[3][5]. The efficacy of this combination may depend on dosing strategies; high-dose steroids can potentially reduce the effectiveness of vancomycin in some cases[3], but adequate serum levels can still be achieved with proper dosing[5].